U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H30N2O2
Molecular Weight 378.5072
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOXAPRAM

SMILES

CCN1CC(CCN2CCOCC2)C(C1=O)(C3=CC=CC=C3)C4=CC=CC=C4

InChI

InChIKey=XFDJYSQDBULQSI-UHFFFAOYSA-N
InChI=1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3

HIDE SMILES / InChI

Molecular Formula C24H30N2O2
Molecular Weight 378.5072
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Doxapram is an analeptic agent (a stimulant of the central nervous system). The respiratory stimulant action is manifested by an increase in tidal volume associated with a slight increase in respiratory rate. A pressor response may result following doxapram administration. Provided there is no impairment of cardiac function, the pressor effect is more marked in hypovolemic than in normovolemic states. The pressor response is due to the improved cardiac output rather than peripheral vasoconstriction. Following doxapram administration, an increased release of catecholamines has been noted. Doxapram produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. It is thought to stimulate the carotid body by inhibiting certain potassium channels. Used as temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Doxapram
Primary
Doxapram

Cmax

ValueDoseCo-administeredAnalytePopulation
0.96 μg/mL
300 mg single, oral
DOXAPRAM plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
272 μg × min/mL
1.5 mg/kg single, intravenous
DOXAPRAM plasma
Homo sapiens
596 μg × min/mL
300 mg single, oral
DOXAPRAM plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
3.4 h
1.5 mg/kg single, intravenous
DOXAPRAM plasma
Homo sapiens
7.5 h
300 mg single, oral
DOXAPRAM plasma
Homo sapiens

Doses

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended dose for I.V. administration is 0.5 – 1 mg/kg for a single injection and at 5-minute intervals. Careful observation of the patient during administration and for some time subsequently are advisable. The ma ximum total dosage by I.V. injection is 2 mg/kg.
Route of Administration: Intravenous
In Vitro Use Guide
Doxapram (1-100 uM) caused rapid, reversible and dose-dependent inhibitions of K+ currents recorded in type I cells of the neonatal rat carotid body (IC50 approximately 13 uM).
Substance Class Chemical
Record UNII
94F3830Q73
Record Status Validated (UNII)
Record Version